Emmaus Life Sciences Inc
OTC:EMMA

Watchlist Manager
Emmaus Life Sciences Inc Logo
Emmaus Life Sciences Inc
OTC:EMMA
Watchlist
Price: 0.014 USD
Market Cap: 894.2k USD

Operating Margin

-10.2%
Current
Declining
by 4.2%
vs 3-y average of -6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-10.2%
=
Operating Income
$-1.2m
/
Revenue
$11.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-10.2%
=
Operating Income
$-1.2m
/
Revenue
$11.9m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Emmaus Life Sciences Inc
OTC:EMMA
894.1k USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
984.9B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.5B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
207.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.1B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.2B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.1B USD
Loading...
No Stocks Found

Market Distribution

Lower than 73% of companies in the United States of America
Percentile
27th
Based on 14 112 companies
27th percentile
-10.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Emmaus Life Sciences Inc
Glance View

Market Cap
894.2k USD
Industry
Pharmaceuticals

Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.

EMMA Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-10.2%
=
Operating Income
$-1.2m
/
Revenue
$11.9m
What is Emmaus Life Sciences Inc's current Operating Margin?

The current Operating Margin for Emmaus Life Sciences Inc is -10.2%, which is below its 3-year median of -6%.

How has Operating Margin changed over time?

Over the last 3 years, Emmaus Life Sciences Inc’s Operating Margin has increased from -65.5% to -10.2%. During this period, it reached a low of -65.5% on Aug 30, 2022 and a high of 12% on Dec 31, 2023.

Back to Top